Claims
- 1. A compound of the following formula: and the salts thereof, whereinA is hydrogen, halo, hydroxy, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, oxo, OY wherein Y is a hydroxy protecting group, or absent; the broken line represents an optional double bond with proviso that if the broken line ia a double bond, then A is absent; Ar1 is phenyl optionally substituted by one or more substituents selected from halo, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkoxy-C1-C4 alkoxy, CF3, carboxy-C1-C4 alkoxy and C1-C4 alkoxy-carbonyl-C1-C4 alkoxy; Ar2 is aryl or heteroaryl selected from phenyl, naphthyl, thienyl, furyl, and pyrrolyl, the aryl or heteroaryl being optionally substituted by one or more substituents selected from halo, hydroxy, amino, nitro, carboxy, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, di C1-C4 alkylamino, halo C1-C4 alkyl, C1-C4 alkythio and sulfonyl methyl; R1 is hydrogen, hydroxy, C1-C4 alkyl, C1-C4 alkoxy or OY wherein Y is a hydroxy protecting group; and R2 and R3, together with the nitrogen atom to which they are attached, form a piperidine or morpholine ring, optionally subsituted by C1-C3 alkyl or halo.
- 2. A compound according to claim 1, whereinA is hydrogen, halo, hydroxy, oxo or OY, or if the broken line is a double bond, then A is absent; Ar1 is phenyl optionally substituted by one to three substituents selected from halo, hyroxy, C1-C4 alkoxy, carboxy C1-C4 alkoxy and C1-C4 alkoxy-carbonyl-C1-C4 alkoxy; Ar2 is phenyl or thienyl, optionally substituted by one to two halo or C1-C4 alkoxy; R1 is hydrogen, hydroxy or C1-C4 alkyl; and R2 and R3, together with the nitrogen atom to which they are attached, form a morpholine ring.
- 3. A compound according to claim 2, whereinA is hydrogen, fluorine, chlorine, hydroxy or OY wherein Y is methoxymethyl or tetrahydropyranyl; or if the broken line is a double bond, then A is absent; Ar1 is phenyl optionally substituted by chlorine, hydroxy, methoxy or carboxymethoxy; Ar2 is phenyl or thienyl, optionally subsituted by chlorine, fluorine or methoxy; R1 is C1-C4 alkyl; and R2 and R3, together with the nitrogen atom to which they are attached, form a morpholine ring.
- 4. A compound according to claim 3, whereinA is hydroxy, fluorine or chlorine; or if the broken line is a double bond, then A is absent; Ar1 is phenyl optionally substituted by carboxymethoxy; Ar2 is phenyl optionally substituted by methoxy; and R1 is C1-C4 alkyl.
- 5. A compound according to claim 3 selected from4{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-morpholinebenzamide.
- 6. A pharmaceutical composition for the treatment of a medical condition for which agonist activity toward opioid kappa receptor is needed, in a mammalian subject, which comprises a therapeutically effective amount of a compound according to claim 1, and a pharmaceutically inert carrier.
- 7. A pharmaceutical composition according to claim 6, which is useful as an analgesic, anesthetic, anti-inflammatory or neuroprotective agent, or useful in the treatment of arthritis, stroke of functional bowel disease.
- 8. A method for the treatment of a medical condition for which agonist activity toward opioid kappa receptor is needed, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound according to claim 1.
Parent Case Info
This is a division of U.S. application Ser. No. 09/254,805 filed Mar. 12, 1999, now U.S. Pat. No. 6,201,007, which, in turn, is the national phase of international application number PCT/IB97/01021 filed Aug. 21, 1997, which, in turn, in a continuation-in-part of international application number PCT/IB96/00957 filed Sep. 18, 1996.
Foreign Referenced Citations (5)
Number |
Date |
Country |
325406 |
Jan 1989 |
EP |
374756 |
Dec 1989 |
EP |
483580 |
Oct 1991 |
EP |
9418165 |
Jan 1994 |
WO |
9630339 |
Mar 1996 |
WO |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/IB96/00957 |
Sep 1996 |
US |
Child |
09/254805 |
|
US |